Stocks
Relay Therapeutics, Inc.RLAY
NASDAQHealthcareBiotechnology$10.36-1.80%
Price as of · delayed, not real-time
Focused on precision medicine, this biotech firm develops therapies targeting protein motion in cancer and genetic diseases. Its computational drug discovery platform attracts investor interest for potential first-in-class treatments, though clinical-stage pipelines carry high risk/reward profiles.
Market Cap: $1.9B52W Range: $1.77 – $11.49
Congressional Interest in Relay Therapeutics, Inc. (RLAY)
1 member of Congress has disclosed 1 trade in Relay Therapeutics, Inc. (RLAY), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading RLAY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | sell | $1K – $15K |